Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 6/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1469049 | 0.86 | BRD4 (0.40) | KMT2ABACE1 | |
| SCHEMBL1468908 | 0.81 | NPC1 (0.48) | — | |
| SCHEMBL1468839 | 0.81 | KCNQ3 (0.50) | KMT2AAAK1PTGS1 | |
| SCHEMBL1468855 | 0.81 | AAK1 (0.47) | KMT2ABACE1AAK1 | |
| SCHEMBL1468035 | 0.81 | HDAC1 (0.45) | KMT2AAAK1KDR | |
| SCHEMBL1467791 | 0.81 | NPC1 (0.51) | KMT2ABACE1 | |
| SCHEMBL1468837 | 0.80 | NPC1 (0.50) | KMT2A | |
| SCHEMBL1469068 | 0.78 | TSHR (0.43) | KMT2A | |
| SCHEMBL1468416 | 0.78 | NPC1 (0.52) | KMT2ABACE1 | |
| SCHEMBL1468895 | 0.78 | SMN1; SMN2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969727-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20160368916-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-9365568-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2990407-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20150322061-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-11-12 | — | — | US | disclosed |
| EP-2307409-B1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8981085-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140243520-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8758830-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140100369-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8545897-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20130045286-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-02-21 | — | — | US | disclosed |
| US-8178131-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-05-15 | — | — | US | disclosed |
| CN-102089307-A | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA INC | 2011-06-08 | — | — | CN | disclosed |
| EP-2307409-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20110070317-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2009140320-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243520-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | LIPE 4729/4885KMT2A 2650/4885BACE1 3796/4885 |
| US-20160368916-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | LIPE 4729/4885KMT2A 2650/4885BACE1 3796/4885 |
| US-20140100369-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | LIPE 4729/4885KMT2A 2650/4885BACE1 3796/4885 |
| US-20110070317-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | LIPE 4727/4885KMT2A 2694/4885BACE1 3670/4885 |
| US-20150322061-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | LIPE 4729/4885KMT2A 2650/4885BACE1 3796/4885 |
| US-20130045286-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, CDKN1A | LIPE 4729/4885KMT2A 2650/4885BACE1 3796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.